Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction

Maria Tavakoli-Ardakani1, Shirin Haghighi2, Shervin Shokouhi3, Bahareh Abtahi-Naeini4, Mohsen Meidani5, Rezvan Hassanpour1, Ali Saffaei6

ABSTRACT

Palmoplantar Erythrodysesthesia Syndrome (PPES) caused by chemotherapeutic agents is rarely life threatening and requires a reduction in dose or discontinuation of chemotherapy. The use of cytarabine and doxorubicin in the treatment of acute myeloid leukemia (AML) along with voriconazole can potentially alter the metabolism of the drugs and cause some interactions. In this study, we presented a case of AML who received cytarabine and doxorubicin as a chemotherapy regimen and voriconazole as a prophylactic anti-fungal. In this combination, voriconazole probably inhibits the P-glycoprotein pump, which leads to an increase in the cytotoxic concentration. The emphasis of this report is the awareness of clinicians and pharmacologists about these interactions.

Keywords: Cytarabine, doxorubicin, voriconazole, palmoplantar; erythrodysesthesia syndrome

Introduction

Palmoplantar Erythrodysesthesia Syndrome (PPES) or hand-foot syndrome (HFS) is an adverse event associated with numerous classic chemotherapeutic agents and newer molecular targeted agents [1]. The primary symptoms, which appear in 3-5 days, are dysesthesia or tingling in the hands or feet with erythema. These symptoms may get worse over the time, thereby occurring desquamation or ulceration. Besides, by progressing PPES, the pain level also increases, especially by grasping objects or walking, which affects the life quality of the patient [2]. PPES seems to be dose-dependent and related to drug concentration and total cumulative dose. Nevertheless, in some cases, no direct relation between dose and severity of PPES was observed [1]. Cytarabine is an anti-metabolite drug, which has an essential role in the treatment of AML. This agent is an anti-metabolite drug, which has an essential role in the treatment of AML. This agent is a substrate for cytochrome P450 (CYP) isoenzymes or P-glycoprotein efflux pumps [3]. In myelosuppressive chemotherapy, neutropenia is a major concern that leads to a devastating infection. Hence, the patients need prophylactic antimicrobial agents such as voriconazole [4]. In some patients, voriconazole can inhibit CYP3A4, CYP2C9, and CYP2C19 in different degrees. Another uncertain interaction mechanism of voriconazole is with the P-glycoprotein efflux pumps [5]. Therefore, this combination therapy can lead to an increase in the concentration of cytotoxic agents in the cells, thereby increasing adverse effects of chemotherapy such as PPES. Here, we describe an AML case with PPES who was received cytarabine, doxorubicin, and voriconazole.

Case Presentation

This is the case of AML-M5 who was a 29-year-old man admitted to hematology ward of Blinded Hospital. Lab data revealed hyperleukocytosis (WBC=155×10⁶ cells/L). Hydroxyurea (CYTO-DROX; Cipla) capsule 1 g four times daily was started for cyto-reduction before initiating chemotherapy. Also, the prophylactic anti-microbial regimen was started based on the last guideline of National Comprehensive Cancer Network (NCCN, version 1.2018), which consist of acyclovir 400 mg tablet (Aciclovir; Ruzdarou) twice day, ciprofloxacin 500 mg (Ciprofloxacin; Farabi) twice a day, and voriconazole 200 mg tablet (Vonafend; Tehrandarou) twice a day. Although the standard antifungal prophylaxis is posaconazole, it is not available in Iran. After seven days of routine evaluation, treatment by cytarabine (Cytosar; Pfizer) at dose 300 mg daily for seven days and doxorubicin (Adriamycin; Pfizer) at dose 80 mg daily for three days as induction regimen was started; and appropriate premedication and supportive medication were considered. After nine days, the chemotherapy complications affected the patient, and the number of white blood cells...
significantly decreased to $20 \times 10^6$ cells/L. In addition, severe nausea, vomiting, diarrhea, abdominal pain, microsites, and hiccups appeared in the patient. The patient became feverish (39.5°C) and was diagnosed with febrile neutropenia. Therefore, broad-spectrum antimicrobial was added to his regimen. In this time, erythema, edema, and palmoplantar thickening with sharp demarcation line in the wrist appeared. The lesions were tender in palpation, and few bullous lesions were seen on the fingers. However, there were no ulcerative or necrotic lesions in this area (Figure 1). These symptoms were seen on feet with less severity (Figure 2). In addition, some rash appeared in his genital areas. These clinical findings were consistent with a diagnosis of PPES. His treatment was continued, and his antifungal regimen was changed into amphotericin (Ambisome; Gilead Sciences) 80 mg daily. In addition, topical Mometasone (Megacorte; kishmedipharm) 0.1% was prescribed for his PPES. All medications were received at a certain dose and were not changed during hospitalization. After 11 days, PPES recovered following peeling of the affected area, and gradually febrile neutropenia was resolved. Finally, after one month, he was discharged, and his clinical condition was stable (Figure 3). To report this case, the informed consent of the patient was obtained.

Discussion
In this study, we presented a case of PPES following induction therapy for AML. This study aimed to show the possible interaction between voriconazole and chemotherapy regimen. It is documented that cytarabine and doxorubicin are substrates for cytochrome P450 isoenzymes or P-glycoprotein efflux pumps [3, 6]. Some cells such as hematopoietic cells and squamous skin cells are more susceptible to chemotherapy. Mrozek Orlowski et al. [7] introduced a reasonable mechanism for this phenomenon. They described that cytotoxic drugs may be excreted in sweat fluid, making hands and feet more susceptible to PPES. These areas are saturated with many eccrine glands. On the other hand, voriconazole can inhibit CYP3A4, CYP2C9, CYP2C19, and probably P-glycoprotein efflux pump. Hence, this process leads to increased adverse effects of chemotherapy on healthy cells. Previous reports regarding PPES following cytarabine or doxorubicin have been summarized in Table 1. Recently, Alzghari et al. [8] reported a case of cytarabine and posaconazole interaction-induced severe PPES and aplasia. Posaconazole inhibits the P-glycoprotein pump, which leads to an increase in the cytarabine concentration. In 2016, Sakurada et al. [9] reported an AML case with PPES who were treated with high-dose

Table 1. Previous cases of PPES induced by Cytarabine or Doxorubicin

| Author            | Year | Sex | Age (Years) | Diagnosis      | Cytotoxic agent | Dose       | Possible Interaction with chemotherapy | Affected area                  |
|-------------------|------|-----|-------------|----------------|----------------|-----------|----------------------------------------|--------------------------------|
| Alzghari et al.   | 2017 | Female | 24          | AML            | Cytarabine     | HiDAC     | Posaconazole                           | Both hands and feet            |
| Sakurada et al.   | 2016 | Female | 40          | AML            | Cytarabine     | HiDAC     | Not mentioned                          | Both hands and feet            |
| Sharma et al.     | 2013 | Female | 28          | AML            | Cytarabine     | Standard  | Not mentioned                          | Both hands and feet            |
| Hwang et al.      | 2012 | Female | 51          | AML after breast cancer | Cytarabine | HiDAC     | Colfarabine                           | Trunk and limbs                |
| Swenson et al.    | 2010 | Female | 69          | Ovarian cancer | Liposomal Doxorubicin | 50 mg/m² | Not mentioned                          | Feet, behind knees, axillary regions and breasts |
| Rosenbeck et al.  | 2011 | Male  | 52          | AML            | Cytarabine     | HiDAC     | Not mentioned                          | Both hands and feet            |
| Damasiewicz et al.| 2007 | Female | 43          | Breast cancer  | Doxorubicin    | 60 mg/m²  | Cyclophosphamide                      | Both hands and feet            |
| Crawford et al.   | 2002 | Male  | 21          | ALL            | Cytarabine     | HiDAC     | Not mentioned                          | Hands                         |
| Gordon et al.     | 1995 | Male  | 30          | Kaposi's sarcoma | Liposomal Doxorubicin | 20 mg/m² | Not mentioned                          | Both hands and feet            |
|                   |      | Male  | 38          | Kaposi's sarcoma | Liposomal Doxorubicin | 20 mg/m² | Not mentioned                          | Hands                         |

Hi-DAC: High-Dose Cytarabine
cytarabine (HiDAC) regimen. This case had a mild rash in her induction therapy phase; so the clinicians decided to prevent the probable PPES with heparinoid lotion and hypoallergenic soap. Their strategy was not completely successful. In 2013, Sharma et al. [10] reported PPES in an AML case after receiving the standard dose of cytarabine. This case received topical ointment, pyridoxine, and soft pads on her lesions. Hwang et al. [11] reported an interesting case of PPES with the affliction of trunk and limbs. She received clofarabine and cytarabine concomitantly. This combination might affect clofarabine or cytarabine metabolism. This case was the first mortality report of severe PPES [11]. Swenson et al. [12] reported a liposomal doxorubicin-induced PPES in a case of ovarian cancer. Her oncologist held the liposomal doxorubicin and reduced its dose by 25% when her treatment resumed. Rosenbeck et al. [13] reported a case of HiDAC-induced PPES. This case received supportive care, and PPES was finally resolved by receiving the last dose of cytarabine after 20 days. In 2007, Damasiewicz et al. [14] reported a case of doxorubicin-induced PPES. This case received doxorubicin and cyclophosphamide for her breast cancer. Crawford et al. [15] reported an ALL case with recurrent PPES. The initial manifestation was a generalized body rash, and they concluded that PPES is a dose-dependent phenomenon in which peak concentration and cumulative dose of cytarabine are involved. Gordon KB et al. [16] also reported two case of Kaposi’s sarcoma who inflicted to PPES after liposomal doxorubicin administration. They found that Kaposi’s sarcoma may trigger PPES in this situation. Current case emphasized the probable interaction between voriconazole as a P-glycoprotein inhibitor and cytarabine-doxorubicin. It should be kept in mind that this was a probable interaction, and hand-foot syndrome recovered after medication modification. To the best of our knowledge, this is the first report of PPES that emphasizes on the interactions of cytarabine and doxorubicin with voriconazole in chemotherapy regimen of patient with AML. Therefore, it is necessary for clinicians and pharmacotherapists to be aware of these interactions and predict the possible complications.

Informed Consent: Written informed consent was obtained from the patient who participated in this study.

Conflict of Interest: The authors have no conflicts of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

References
1. Miller KK, Gorecy L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 2014; 71: 787-94. [CrossRef]
2. Mangili G, Petrone M, Gentile C, De Marzi P, Viganò R, Rabaïotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: The role of regional cooling. Gynecol Oncol 2008; 108: 332-5. [CrossRef]
3. Choi SJ, Shin SC, Choi JS. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin. Arch Pharm Res 2011; 34: 309-15. [CrossRef]
4. Tavakoli-Ardakani M, Eshraghi A, Hajhossein Talasaz A, Salamzadeh J. A Drug Utilization Evaluation Study of Amphotericin B in Neutropenic Patients in a Teaching Hospital in Iran. IJPR, 2012; 11: 151-6.
5. Nivoix Y, Ubeaud-Sequier G, Engel P, Leveque D, Herbrecht R. Drug-drug interactions of triazole antifungal agents in multimorbied patients and implications for patient care. Curr Drug Metab 2009; 10: 395-409. [CrossRef]
6. Colburn DE, Giles FJ, Oladovich D, Smith JA. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, irinotecan and caspofungin. Hematology 2004; 9: 217-21. [CrossRef]
7. Mrozek-Orlowska ME, Frye DK, Sanborn HM. Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum 1999; 26: 753-62.
8. Alighari SK, Seago SE, Cable CT, Herrington JD. Severe palmar-plantar erythrodysesthesia and aplasia in an adult undergoing re-induction treatment with high-dose cytarabine for acute myelogenous leukemia: a possible drug interaction between posaconazole and cytarabine. J Oncol Pharm Pract 2017; 23: 476-80. [CrossRef]
9. Sakurada H, Aoi M, Yuge M, et al. A Case of A Multidisciplinary Team Approach to Serious Hand-Foot Syndrome Induced by High-Dose Cytarabine Therapy. Gan To Kagaku Ryoho 2016; 43: 917-9.
10. Sharma A, Baghmar S. Hand foot syndrome associated with standard dose cytarabine. Indian J Med Paediatr Oncol 2013; 34: 333. [CrossRef]
11. Hwang YY, Trendell-Smith NJ, Yeung CK, Kwong YL. Fatal palmar-plantar erythrodysesthesia after clofarabine and cytarabine chemotherapy. Acta Haematol 2012; 128: 151-3. [CrossRef]
12. Swenson KK, Bell EM. Hand-foot syndrome related to liposomal doxorubicin. Oncol Nurs Forum 2010; 37: 137-9. [CrossRef]
13. Rosenbeck L, Kiel PJ. Images in clinical medicine. Palmar-plantar rash with cytarabine therapy. N Engl J Med 2011; 364: e5.
14. Damasiewicz MJ, Chonh FJ, Hayes T. Severe palmar-plantar erythema in a patient with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. Intern Med J 2007; 37: 505-6. [CrossRef]
15. Crawford JH, Eikelboom JW, McQuillan A. Recurrent palmar-plantar erythrodysesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia. Eur J Haematol 2002; 69: 315-7. [CrossRef]
16. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995; 75: 2169-73.